Distinct MHC gene expression patterns during progression of melanoma
暂无分享,去创建一个
Joel Greshock | Xiaolu Yang | Meenhard Herlyn | Katherine Nathanson | B. Weber | M. Herlyn | K. Nathanson | J. Greshock | Xiaolu Yang | Jia Huang | Jia Huang | Y. Degenhardt | Barbara Weber | Yan Degenhardt | Galene Horiates | Galene Horiates
[1] K. Wright,et al. Epigenetic regulation of MHC-II and CIITA genes. , 2006, Trends in immunology.
[2] M. Jager,et al. Epigenetic silencing of MHC2TA transcription in cancer. , 2006, Biochemical pharmacology.
[3] N. Cascinelli,et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. , 2003, Cancer research.
[4] E. Shevach,et al. Recognition of a New ARTC1 Peptide Ligand Uniquely Expressed in Tumor Cells by Antigen-Specific CD4+ Regulatory T Cells1 , 2005, The Journal of Immunology.
[5] N. Mulder,et al. The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. , 1993, Anticancer research.
[6] R. Salgia,et al. MET pathway as a therapeutic target. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] F. Marincola,et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.
[8] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[9] N. Hynes,et al. ErbB receptors and signaling pathways in cancer. , 2009, Current opinion in cell biology.
[10] T. Tomonaga,et al. Strong HLA‐DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c‐myc suppression by interferon‐γin situ , 2006, Cancer science.
[11] B. Seliger,et al. Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome , 2005, Clinical Cancer Research.
[12] B. Seliger,et al. Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. , 2006, Cancer research.
[13] P. Stern,et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.
[14] H. Kuipers,et al. Transcriptional regulation of antigen presentation. , 2004, Current opinion in immunology.
[15] F. Garrido,et al. HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank , 2009, Cancer Immunology, Immunotherapy.
[16] L. Staudt,et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. , 2004, Blood.
[17] F. Aoudjit,et al. HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells. , 2004, Experimental cell research.
[18] D. Ruiter,et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. , 1988, Cancer research.
[19] G. Pawelec,et al. High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity , 2005, Cancer Immunology, Immunotherapy.
[20] John Quackenbush,et al. CGHAnalyzer: a stand-alone software package for cancer genome analysis using array-based DNA copy number data , 2005, Bioinform..
[21] S. Ferrone,et al. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. , 2006, Cancer research.
[22] D. Schadendorf,et al. Patterns of constitutive and IFN-γ inducible expression of HLA class II molecules in human melanoma cell lines , 2007, Immunogenetics.
[23] M. Maio,et al. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? , 2003, Oncogene.
[24] Joel Greshock,et al. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization , 2005, Breast Cancer Research.
[25] Vladimir Brusic,et al. MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] M. Wigler,et al. Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. , 2003, Cancer cell.
[27] B. Weber,et al. SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant , 2004, Cancer Research.
[28] J. M. Boss,et al. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[29] D. Elder,et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. , 2003, Cancer research.
[30] G. Pawelec,et al. Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines , 2008, Cancer Immunology, Immunotherapy.
[31] J. Squire,et al. Chromosome 6p amplification and cancer progression , 2006, Journal of Clinical Pathology.
[32] D. Schadendorf,et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. , 2006, Pigment cell research.
[33] B. Weber,et al. Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma‐derived cell lines , 2009, Genes, chromosomes & cancer.
[34] S. Ferrone,et al. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] S. Ferrone,et al. Immune selective pressure and HLA class I antigen defects in malignant lesions , 2006, Cancer Immunology, Immunotherapy.
[36] B. Peterlin,et al. Expression of MHC II genes. , 2006, Current topics in microbiology and immunology.
[37] H. Byers,et al. Pathologic parameters in the diagnosis and prognosis of primary cutaneous melanoma. , 1998, Hematology/oncology clinics of North America.
[38] K. Ozato,et al. Induction of MHC class I expression by the MHC class II transactivator CIITA. , 1997, Immunity.
[39] F. Marincola,et al. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.
[40] J. Ting,et al. Constitutive Expression of MHC Class II Genes in Melanoma Cell Lines Results from the Transcription of Class II Transactivator Abnormally Initiated from Its B Cell-Specific Promoter1 , 2001, The Journal of Immunology.
[41] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[42] P. Robbins,et al. A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.
[43] S. Ferrone,et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. , 2006, Cancer research.
[44] W. Reith,et al. Regulation of MHC class II genes: lessons from a disease. , 1996, Annual review of immunology.
[45] P. J. van den Elsen,et al. DNA methylation and expression of major histocompatibility complex class I and class II transactivator genes in human developmental tumor cells and in T cell malignancies. , 2003, Clinical immunology.
[46] R. Ádány,et al. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. , 2001, Cytometry.
[47] G. Fleuren,et al. Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer , 2000, The Journal of experimental medicine.